Aptamer-Based Cross-Linked Materials for Glucose-Sensing Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems for diabetes mellitus, particularly those using lectins like Con A, face challenges such as uncontrolled insulin release, potential toxicity, and immune responses, necessitating the development of alternative multivalent glucose-binding molecules that can function safely and effectively in vivo.
Innovation Solution
The use of cross-linked materials incorporating multivalent polynucleotide aptamers that bind target molecules, such as glucose, and conjugates with affinity ligands, which compete for binding, allowing controlled release of drugs in response to specific glucose concentrations, replacing traditional lectins with safer alternatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lectins like Con A are used as multivalent glucose-binding molecules, then glucose binding capability is improved, but toxicity and immune responses increase
Solution Approach 1:
The patent uses aptamers as intermediary molecules that bind glucose with high affinity and specificity, replacing lectins like Con A. These aptamers serve as safe mediators that achieve the desired glucose binding function without the toxic and immunogenic side effects of lectins, thus resolving the contradiction between binding capability and safety
Solution Approach 2:
The patent changes the chemical and biological parameters of the glucose-binding molecule from protein-based lectins to nucleic acid-based aptamers. This parameter change fundamentally alters the safety profile while maintaining or improving glucose binding affinity and specificity, eliminating toxicity and immune response issues
2Device complexity
If traditional controlled-release systems are used, then drug delivery is simplified, but release is uncontrolled and not proportional to metabolite concentrations
Solution Approach 1:
The patent implements a feedback mechanism where aptamers continuously sense glucose concentrations and dynamically regulate insulin release accordingly. The aptamer-insulin conjugate system automatically adjusts release rates based on real-time metabolite levels, creating a closed-loop controlled-release system that is both precise and physiologically appropriate
Solution Approach 2:
The patent transforms the static, passive controlled-release system into a dynamic, responsive system. The aptamer component provides real-time sensing capability that enables the delivery system to adapt its release profile dynamically based on changing glucose concentrations, achieving proportional release without excessive complexity
3Productivity
If mitogenic lectins are used to bind carbohydrates on lymphocytes, then cell proliferation is stimulated, but inflammation and cytotoxicity occur
Solution Approach 1:
The patent extracts only the desired functional property (glucose binding capability) from lectins and implements it through aptamers, while leaving behind the harmful properties (mitogenicity, immunogenicity). This selective extraction approach achieves cell proliferation stimulation through appropriate mechanisms without the harmful side effects of lectin-mediated lymphocyte activation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a controlled and proportional release of insulin in response to glucose levels, reducing toxicity risks and immune responses, providing a more physiological and effective insulin delivery system.
Implementation Method 1
conjugates are cross-linked within the material as a result of non-covalent interactions between aptamers and affinity ligands on different conjugates
Implementation Method 2
the two or more affinity ligands compete with the target molecule for binding with the aptamers
Data Source
AI summary
In one aspect, the disclosure provides cross-linked materials that include multivalent polynucleotide aptamers that bind a target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the target molecule for binding with the aptamers and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between aptamers and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of the target molecule. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label. The drug, detectable label and affinity ligands may be covalently or non-covalently bound to the conjugate framework.